Palvella Therapeutics, Inc. Cash Equivalents, at Carrying Value
Palvella Therapeutics, Inc. (PVLA) had Cash Equivalents, at Carrying Value of $34.90 million as of 2021-09-30, per its 10-Q filed 2021-11-02.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2021-11-02
- 2021-09-30: Cash Equivalents, at Carrying Value $34.90M.
- 2021-06-30: Cash Equivalents, at Carrying Value $91.80M.
- 2021-03-31: Cash Equivalents, at Carrying Value $49.70M.
- 2020-12-31: Cash Equivalents, at Carrying Value $64.00M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2021-09-30 | $34.90M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $91.80M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $49.70M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $64.00M 10-Q · filed 2021-11-02 |
| 2019-12-31 | $89.28M 10-K · filed 2020-03-13 |
| 2018-12-31 | $71.94M 10-K · filed 2020-03-13 |
| 2017-12-31 | $62.85M 10-K · filed 2019-03-18 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-13 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-11 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 |
| 2016-12-31 | $0.00 10-Q · filed 2017-11-13 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |